Cell-Derived Microparticles in the Pathogenesis of Cardiovascular Disease Friend or Foe? by Tushuizen, M.E. et al.
Maarten E. Tushuizen, Michaela Diamant, Augueste Sturk and Rienk Nieuwland
Friend or Foe?
Cell-Derived Microparticles in the Pathogenesis of Cardiovascular Disease :
ISSN: 1524-4636 
Copyright © 2010 American Heart Association. All rights reserved. Print ISSN: 1079-5642. Online
7272 Greenville Avenue, Dallas, TX 72514
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association.
doi: 10.1161/ATVBAHA.109.200998
2011, 31:4-9Arterioscler Thromb Vasc Biol 
 http://atvb.ahajournals.org/content/31/1/4
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://atvb.ahajournals.org//subscriptions/
Biology is online at 
Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular
 by guest on March 28, 2012http://atvb.ahajournals.org/Downloaded from 
ATVB in Focus
Microparticles
Series Editors: Chantal M. Boulanger and Françoise Dignat-George
Cell-Derived Microparticles in the Pathogenesis of
Cardiovascular Disease
Friend or Foe?
Maarten E. Tushuizen, Michaela Diamant, Augueste Sturk, Rienk Nieuwland
Abstract—Microparticles are ascribed important roles in coagulation, inflammation, and endothelial function. These
processes are mandatory to safeguard the integrity of the organism, and their derangements contribute to the
development of atherosclerosis and cardiovascular disease. More recently, the presumed solely harmful role of
microparticles has been challenged because microparticles may also be involved in the maintenance and preservation
of cellular homeostasis and in promoting defense mechanisms. Here, we summarize recent studies revealing these 2
faces of microparticles in cardiovascular disease. (Arterioscler Thromb Vasc Biol. 2011;31:4-9.)
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Cardiovascular disease (CVD) remains the leading causeof death in developed countries despite advances in
treatment.1 Although assessment and treatment of traditional
cardiovascular risk factors, including hypertension, diabetes
mellitus, and smoking, play a central role in primary and
secondary disease prevention, even adequate treatment of
these risk factors does not completely reduce the risk of CVD.
Therefore, a quest for novel biomarkers or mediators is
ongoing, which may help us to gain more insight into the
mechanisms leading to the development of atherosclerosis,
the underlying cause of CVD.2 Cumulating evidence suggests
that microparticles (ie, vesicles budded from the outer mem-
brane of cells on their activation or as part of the apoptosis of
the cell) and other microvesicles may provide such a media-
tor. Since their identification in the late 1960s, the scientific
and clinical interest in cell-derived microparticles has in-
creased substantially. This is not surprising because micro-
particles affect coagulation and inflammation, along with
endothelial function, cellular survival, and intercellular
communication.3–5
Most microparticles in blood are derived from platelets,
whereas microparticles from erythrocytes, granulocytes,
monocytes, lymphocytes, and endothelial cells are also pres-
ent, albeit at much lower numbers. There are substantial
differences between the fractions of microparticles or sub-
populations in the blood of healthy subjects and those present
in patients suffering from diseases with increased thrombo-
embolic risk or vascular damage, such as atherosclerotic
vascular disease, sepsis, diabetes, chronic severe hyperten-
sion, and preeclampsia.3–5 Accordingly, in patients with acute
myocardial infarction, elevated numbers of microparticles are
present compared with healthy controls.3,6,7 Moreover, sub-
types of microparticles differ between patients with stable
angina and those with acute coronary syndromes or myocar-
dial infarction.7,8 Earlier, it was demonstrated that micropar-
ticles from patients with myocardial infarction cause endo-
thelial dysfunction and might contribute to the general
vasomotor dysfunction observed after myocardial infarction.9
The clinical relevance of the presence of microparticles in
the blood of healthy subjects is unclear but can be regarded as
a reflection of the dynamics of their production by resting,
activated, and apoptotic cells and their clearance. In vascular
disease states, it remains to be elucidated whether micropar-
ticles are a cause or a consequence of the condition because
disease-related factors, such as infectious agents, cytokines,
and metabolic disturbances, are all known to affect the release
of microparticles.3–5 Still, it is likely that microparticles
contribute to the severity of disease because they can dissem-
inate procoagulant and proinflammatory activities. Therefore,
microparticles may be viewed as part of a cascade of
reactions in response to various stimuli. The stimulus that
leads to their generation determines their numbers, size,
biochemical composition, and functional characteristics. Mi-
croparticles are likely to be important and essential mediators
of physiological and pathological conditions; in this review,
we will focus on the clinical relevance of microparticles in
CVD.
Microparticles: Friend or Foe?
All body fluids, ranging from blood and urine to lacrima and
mother’s milk, and human atherosclerotic plaques contain
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cell-derived vesicles. Microparticles as outer membrane–
derived vesicles are 1 type of vesicle, as are exosomes, which
are extruded from intracellular multivesicular bodies once
they fuse with the outer membrane. Different types of
vesicles originating from a variety of cells are concurrently
present in body fluids under physiological and pathological
conditions. Most clinical studies thus far have focused on the
presence of microparticles in blood (ie, their cellular origin,
composition, and function in disease).3–5
Microparticles may not only have deleterious effects by
promoting coagulation and inflammation or by modifying
endothelial function, which all contribute to the development
of CVD; but may also have beneficial effects. First, recent
studies have shown that microparticles are efficient vectors
that exchange biological information between cells (intercel-
lular communication).3–5 Second, the release of micropar-
ticles protects cells against the consequences of external
stimuli or stress. Endothelial cells escape from complement-
induced lysis by releasing microparticles carrying the lytic
complement C5b-9 complex.10 Similarly, the release of mi-
croparticles protects cells against an overshoot in (internal)
cellular reactions triggered by external stressors. Regarding
the latter, microparticles play a role in “cellular waste
management” because they contain increased (compared with
parent cell) concentrations of chemotherapeutics, oxidized
phospholipids, or caspase 3.3–5 Microparticles of viable non-
apoptotic cells, including endothelial cells, contain caspase 3
in vitro and in vivo.11–13 Endothelial cells accumulate caspase
3 and undergo apoptosis when the release of (caspase
3–containing) microparticles is inhibited,13 indicating that the
release of microparticles is part of a protective mechanism to
prevent the intracellular accumulation of caspase 3 at dan-
gerously high levels. Possibly, caspase 3 facilitates its own
removal from cells by cleaving several kinases, including
Rho-associated kinase I and p21-activated kinase, which
become constitutively active on cleavage and promote mem-
brane blebbing. On incubation of human endothelial cells
with simvastatin at clinically relevant concentrations, the
cells remain viable and seemingly unchanged; however, a
marked increase in caspase 3–containing microparticles is
observed, suggesting that an increased release of caspase
3–containing microparticles is needed to help the cells to
remain healthy and viable.14 The effects of statins on the
release of microparticles may depend on the cell types
studied; the experimental conditions, including the concen-
tration and type of statin used; or the combined application of
a statin with a proinflammatory or proapoptotic inducer. It is
beyond the scope of this brief review to elaborate on this
topic. In line with our results are the findings that in patients
with subclinical or less occlusive atherosclerosis, more endo-
thelial microparticles are present when compared with pa-
tients with established or symptomatic atherosclerosis,8,15
suggesting that the ability of the endothelium to release
microparticles depends on its integrity and viability. In other
words, if the ability of the endothelium to release micropar-
ticles becomes impaired or inhibited, the integrity and viabil-
ity of the cells may deteriorate.
Microparticles and Coagulation
The most described and reviewed characteristic of circulating
and atherosclerotic plaque–derived cell-derived micropar-
ticles is their procoagulant phenotype. By exposing phospha-
tidylserine and sometimes tissue factor (TF), microparticles
can initiate and propagate coagulation.3–5 However, TF often
seems to be exposed by circulating microparticles in a
noncoagulant form, as shown in patients with type 2 diabe-
tes.16 This inactive or encrypted TF may become procoagu-
lant after the capture of TF-bearing microparticles in the
developing thrombus.17 This is supported by the recent
finding that those patients with acute ST-segment elevation
myocardial infarction who had the highest plasma level of
TF-exposing microparticles were characterized by a proco-
agulant phenotype, as reflected by increased plasma levels of
thrombin-antithrombin complexes, and by an increased risk
of fibrinolysis failure.18 Furthermore, microparticles accumu-
late in human atherosclerotic plaques, and these micropar-
ticles have an increased ability to initiate TF-dependent
coagulation compared with the plasma microparticles.19
The capture of TF-bearing microparticles in the developing
thrombus, finally resulting in arterial occlusion, is thought to
be mediated by P-selectin and/or CD36 exposed on activated
platelets.17,20 Important factors in deencryption of the TF
procoagulant activity are protein disulfide isomerases (PDIs),
believed to be released from platelets and endothelial cells. In
addition, platelet microparticles can expose PDIs.21 Recently,
it was demonstrated that fibrin generation in vivo required
PDI released from endothelial cells, whereas platelet-derived
PDI contributed only to the total amount of thrombus-
associated PDI (but was not required).22
The relationship between microparticles and coagulation
and other processes is complex. For instance, under normal
conditions, a continuous low-grade generation of thrombin is
essential for activation of protein C, which, in turn, efficiently
inhibits additional thrombin generation by inactivating coag-
ulation factors Va and VIIIa. Previously, it was reported that
plasma samples from healthy humans containing low levels
of microparticles have relatively high concentrations of
thrombin-antithrombin and prothrombin fragment 12, sug-
gesting that in these subjects insufficient activation of protein
C may occur.23–25 Under clinical conditions, in which ele-
vated levels of microparticles can be present and in which
microparticles may expose coagulant TF, this inverse corre-
lation is no longer present; then, microparticles are more
directly associated with in vivo coagulation activation.
Microparticles are thought to contribute to acute thrombus
formation via various mechanisms; they also contribute to
anticoagulant responses to modulate an adequate and physi-
ological coagulation response. However, additional research
is essential to better understand their contribution to coagu-
lation in clinical conditions, including CVD.
Microparticles and Inflammation
Similar to coagulation, inflammatory processes contribute to
the pathogenesis of atherothrombotic vascular disease.26 Pa-
tients with elevated plasma levels of inflammation markers,
including C-reactive protein, are at a high risk of developing
CVD, including those with diabetes, metabolic syndrome,
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and chronic systemic inflammatory or autoimmune disease
(eg, rheumatoid arthritis).26,27 Microparticles may contribute
to inflammatory responses by various mechanisms.3–5 For
example, microparticles from leukocytes stimulate the ex-
pression of proinflammatory genes in endothelial cells, lead-
ing to the production of cytokines and leukocyte–endothelial
cell adhesion molecules in vitro.28 Furthermore, micropar-
ticles in plasma samples from high-risk patients expose
complement components (C1q, C3, and C4) and several
complement activator molecules (eg, C-reactive protein) in
rheumatoid arthritis patients and IgG (but not C-reactive
protein) in patients with myocardial infarction.29,30
But again, microparticles may also have a beneficial
function in the inflammatory response. Microparticles from
polymorphonuclear leukocytes contain the functionally active
anti-inflammatory protein annexin 1, and annexin 1–contain-
ing microparticles inhibit the interaction between leukocytes
and endothelial cells in vitro and in an animal model in
vivo.31 Therefore, in health, microparticles can affect both
proinflammatory and anti-inflammatory processes, thus ensuring
an appropriate inflammatory response. In diseases such as
rheumatoid arthritis or atherosclerosis, their increased and pro-
longed presence, altered properties, and activities may become
harmful and contribute to overall vascular deterioration.
Microparticles and Endothelial Functions
Under normal conditions, the multiple functional character-
istics of the endothelium, in addition to anti-inflammation and
anticoagulation, include regulation of vascular tone, vascular
wall permeability, and cell growth; collectively, they protect
the vascular system. An altered function of endothelial NO
synthase, decreased bioavailability of NO, or both are funda-
mental abnormalities that can lead to the pathophysiological
manifestations of endothelial dysfunction.32 In vitro, micro-
particles from various cellular or disease origins or both
induce endothelial dysfunction, especially by altering the
balance between NO and reactive oxygen species (ROS)
production and release.33–35 For example, microparticles from
T lymphocytes decrease NO production and increase oxida-
tive stress in endothelial cells.35 These effects are associated
with a reduction of endothelial NO synthase activity, which
depends on phosphatidylinositol-3-kinase (PI3K), extracellu-
lar signal–regulated kinase 1/2, and nuclear factor B path-
ways. The increase of ROS production that is downregulated
by the PI3K pathway involves xanthine oxidase and nuclear
factor B pathways. Also, exposure to microparticles results
in increased caveolin-1 expression and decreased phosphoryla-
tion; these effects are independent of the PI3K and extracellular
signal–regulated kinase 1/2 cascade, respectively.35 In vivo,
NO-associated vasodilatation after shear stress can be mea-
sured by ultrasonography of the brachial artery (flow-
mediated dilatation) and is associated with the viability of the
endothelium. Impaired flow-mediated dilatation has been
associated with the presence of endothelial microparticles in
various clinical conditions.36,37
In contrast to the harmful role of microparticles, they may
actually improve endothelial dysfunction. T-cell micropar-
ticles carrying the morphogen sonic hedgehog induced NO
production directly by the sonic hedgehog pathways (involv-
ing PI3K and protein kinase B [Akt]).38 By using a model of
ischemia/reperfusion in mice, these sonic hedgehog–pres-
enting microparticles enhanced NO-mediated relaxation of
mouse coronary arteries in vivo in response to acetylcholine,
which was accompanied by an increase of NO production in
tissues and blood even after ischemia/reperfusion. Moreover,
microparticles, especially those of nonplatelet origin, released
during sepsis (the clinical condition that ultimately challenges
the endothelium) were protective against vascular hyporeac-
tivity, which accounts for hypotension in patients with septic
shock.39 In agreement with these results, Soriano and cowork-
ers40 have shown that elevated levels of endothelial and
platelet microparticles predict a more favorable outcome in
severe sepsis in terms of mortality rate and organ dysfunction.
Evidently, microparticles are able to restore endothelial injury
through their dual ability to increase NO and reduce ROS. In
summary, microparticles can have both detrimental and
beneficial effects on endothelial functions, especially by
altering the balance between NO and ROS production and
release. It seems that these effects are dependent on the
specific stimulus underlying the release of microparticles by
their parent cells.
Finally, circulating and atherosclerotic plaque-derived mi-
croparticles can affect angiogenesis. One characteristic fea-
ture of vulnerable atherosclerotic plaques is an increased
number of vasa vasorum. Whereas microparticles from plate-
lets and endothelial cells were shown to promote and inhibit
angiogenesis in vitro in initial studies, respectively, more
recently, researchers showed that microparticles isolated from
human atherosclerotic plaques promote endothelial cell pro-
liferation in vitro and stimulate angiogenesis in vivo, respec-
tively. Thus, microparticles may contribute to neovascular-
ization of atherosclerotic plaques, thereby affecting the
vulnerability of rupture.41–43
Microparticles and CVD
In the light of the previously described procoagulant and
proinflammatory properties of microparticles, together with
the association between elevated numbers of microparticles
and clinical CVD, the prevailing view is that circulating
microparticles are harmful, contributing to CVD and risk of
CVD. However, as previously outlined, in addition to their
potentially harmful effects, cell-derived microparticles may
also be beneficial and protect against cellular and vascular
damage. This is summarized in the Figure. Therefore, it is not
surprising that both elevated and lower levels of circulating
microparticles have been associated with (risk factors of)
CVD. For example, cigarette smoking is a well-established
risk factor for CVD and has been reported to lead to
hemostatic, platelet, and endothelial abnormalities.44 Al-
though the numbers of platelet microparticles tended to be
lower in young males compared with nonsmoking controls,
levels of circulating endothelial microparticles were elevated
on secondhand smoke exposure, and exposure of human
monocytes to smoke increased the release of (TF-exposing)
microparticles.45–47 It is clear that smoking affects the release
of microparticles; however, this effect is likely to be cell type,
concentration, and duration dependent.
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Interestingly, elevated platelet microparticles were de-
scribed in patients with both type 1 and 2 diabetes, hyperlip-
idemia, obesity/metabolic syndrome, and hypertension.3,5
Thus, in plasma samples from patients with chronic severe
hypertension compared with patients with mild hypertension
and controls, more microparticles exposing platelet endothelial
cell adhesion molecule-1 (PECAM-1) (CD31), but not glyco-
protein Ib (CD42) (ie, microparticles presumably of endothelial
or platelet origin or both), were found.48,49 In these patients,
elevated numbers of microparticles are likely to reflect the
cellular stress of endothelial cells and platelets. In addition,
microparticles from plasma of hypertensive patients with
albuminuria attenuated proliferation and migration of endo-
thelial progenitor cells and increased endothelial hydrogen
peroxide production, cellular senescence, and apoptosis com-
pared with microparticles from hypertensive patients with
normoalbuminuria.50 This suggests that the release of micro-
particles contributes to the progression of endothelial dam-
age, which could then result in a vicious circle.
High numbers of circulating microparticles of different
cellular origin have been associated with subclinical athero-
sclerosis, measured by carotid intima-media thickness and
coronary artery calcifications, quantified by computed to-
mography, as previously described.8,15,51–53 Recently, it was
proposed that circulating microparticles are the major factor
associated with carotid artery remodeling, with high numbers
of circulating microparticles preventing compensatory re-
modeling in vessels with increased carotid intima-media
thickness.53 Moreover, T-cadherin–exposing endothelial mi-
croparticles were elevated in patients with subclinical athero-
sclerosis compared with healthy subjects and patients with
established coronary artery disease, suggesting that the shed-
ding of T-cadherin–positive microparticles represents a pro-
tective mechanism that can shift the balance in cellular stress
response to the prosurvival signaling branches, which is only
later followed by deleterious and apoptotic phases.15 This
indicates that the release of microparticles attenuates com-
pensatory outward artery remodeling in patients with (sub-
clinical) atherosclerosis. However, longitudinal, rather than
the presently available cross-sectional, studies are required to
definitively demonstrate the causative role of microparticles
in arterial remodeling.
An important clinical question is whether microparticles are
markers of CVD risk and whether they can be used as indepen-
dent predictors of CVD outcome in relevant populations. Re-
cently, the associations of the Framingham risk score and
numbers of platelet-, leukocyte-, endothelial progenitor cell–,
and endothelium-derived microparticles were reported.52,54,55
From these 4 studies, only 1 included a prospective investi-
gation, in which 488 patients with various CVD risk factors
were observed for a mean of 36 months.55 The addition of
endothelial (CD144) microparticles to the Framingham risk
model improved the classification of risk and appeared as a
significant and independent predictor of future CVD events in
a high-risk population.55 These results are promising and
imply that more prospective studies are needed to further
detail the prognostic value of cell-derived microparticles in
individuals at high risk for CVD. The lack of large-scaled
studies in which microparticles are measured routinely may
be partly because of the fact that the measurement of
microparticles is still complex and elaborate. The detection
and characterization of (individual) microparticles and other
vesicles remain difficult because of their small size and
heterogeneity, which has led to confusing and sometimes
conflicting results between laboratories.56 In addition, the
detection of rare microparticles (eg, endothelial micropar-
ticles) remains a real challenge. Although some laboratories
have used antibodies against specific endothelial proteins,
other investigators56,57 have used non–endothelial-specific
antibodies or combinations.
Conclusion
Because their presence and role in various diseases has been
recognized, the interest in cell-derived microparticles, also as
markers or mediators in the development of CVD, has grown
substantially. During the past years, the role of microparticles
in the development of CVD has changed from “platelet dust”
or artifacts to novel and possibly essential elements in cellular
Figure. Proposed model describing the
role of microparticles in cardiovascular
health and disease. Cells release micro-
particles (left, green) to ensure homeosta-
sis. These microparticles contribute to the
regulation of physiological processes,
including (anti)coagulation, inflammation,
and regulation of endothelial functions.
Under abnormal (stress) conditions, cells
release microparticles that differ in num-
bers, composition, and function (right,
red), thereby contributing to a procoagu-
lant and proinflammatory phenotype, en-
dothelial dysfunction, as part of the devel-
opment of CVD.
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homeostasis and communication. Furthermore, the release of
microparticles contributes to the activation of (intentionally
protective) protein cascades, such as coagulation, inflamma-
tion, and endothelial dysfunction (Figure), which all facilitate
atherogenesis. Therefore, microparticles may not only reflect
the presence of CVD but also play a causative role in its
development.
On the other hand, the release of microparticles can protect
cells from dangerous or redundant products, compounds, or
cellular waste that may accumulate in response to cell stress
induced by, for example, CVD risk factors. Thus, micropar-
ticles can contribute to cellular homeostasis. Although the
release of microparticles may be beneficial to the individual
cell releasing them, this release can also have paracrine and
even systemic effects, which affects the surrounding cells.
Whether cell-derived microparticles are a cause, conse-
quence, or both of CVD remains to be established. Large-
scaled prospective studies, rather than the presently available
cross-sectional studies, are mandatory to more definitively
demonstrate the interrelation of changes in occurrence, phe-
notype, and function of microparticles and the incidence and
progression of CVD in various populations.
Future Directions
Future research should focus on further characterization of
cell-derived microparticles as opposed to exosomes and
possibly other cell-derived vesicles in various diseases. More-
over, multidisciplinary research should focus on further
refinement and validation of detection methods of micropar-
ticles. These methodological investigations may contribute to
more uniformity and validation of microparticle quantifica-
tion, detection, identification of their parent cell, and bio-
chemical and functional characterization. With a multidisci-
plinary approach and the proper verification studies in
relevant patient populations, microparticles may prove to be
true biomarkers of disease state and progression.
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